Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645746 | 0.79 | CA1 (0.54) | PTGS1GABRA1GABRB1CA1CA2 | |
| SCHEMBL8823987 | 0.77 | AKR1C3 (0.36) | PTGS1GRM1LMNA | |
| SCHEMBL60358 | 0.76 | PTGS2 (0.49) | PTGS2PTGS1GRM1GAALMNA | |
| SCHEMBL490376 | 0.75 | PTGS2 (0.51) | PTGS2PTGS1GRM1FFAR1GAA | |
| SCHEMBL31402519 | 0.75 | PTGS2 (0.51) | PTGS2PTGS1GRM1FFAR1GAA | |
| SCHEMBL31139063 | 0.74 | MT-CO2 (0.40) | GRM1GABRA1GABRB1CA1CA2 | |
| SCHEMBL3833416 | 0.74 | PTGS1 (0.47) | PTGS2PTGS1GRM1GAAACHE | |
| SCHEMBL7102472 | 0.71 | PTGS2 (0.47) | PTGS2PTGS1GABRA1GABRB1CA1 | |
| SCHEMBL28238190 | 0.69 | TRPA1 (0.62) | PTGS2PTGS1GAALMNAHTT | |
| SCHEMBL11430189 | 0.69 | BCL2 (0.47) | GRM1GABRA1GABRB1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8505730-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120312717-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8273791-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2087880-A2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | Jr Chem, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2009-07-09 | — | — | US | disclosed |
| US-6960347-B2 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2005-11-01 | — | — | US | disclosed |
| US-20010036446-A1 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | RARG, RARA, RXRG | PTGS2 1236/4885PTGS1 1464/4885GRM1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.